This is the authors' abstract. We don't add key points for this paper.
> 1 mm), and it could not be advanced further. The exceptionally low hit rate observed here suggests that PrP is a difficult target for small-molecule binders. Whereas orthogonal binder discovery methods could yield high-affinity compounds, non-small-molecule modalities may offer independent paths forward against prion disease.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Reidenbach et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: